Supplemental Material from An Integrated Analysis of Heterogeneous Drug Responses in Acute Myeloid Leukemia That Enables the Discovery of Predictive Biomarkers

Supplemental Methods Supplemental Table 1 Supplemental Figures 1-6 1. Pretreatment with cytarabine potentiates the effects of FED in AML xenografts. Supplemental Figure 2. PF cytometry analysis of AML samples. Supplemental Figure 3. Immunophenotypic and phosphoprotein signaling heterogeneity of AML patient samples. Supplemental Figure 4. PF analysis of validation cohort samples Supplemental Figure 5. Effects of FED treatment on FLT3 activity. Supplemental Figure 6. Effects of FED and DAS treatment on pSTAT5, pSRC and pTyr in BCR-ABL1+ AML samples. Supplemental Table 1: Characteristics of patient samples studied in initial and validation cohorts.